A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

Kami Maddocks; Amy S. Ruppert; Rebekah Browning; Jeffrey Jones; Joseph Flynn; Cheryl Kefauver; Yue Gao; Yao Jiang; Darlene M. Rozewski; Ming Poi; Mitch A. Phelps; Erica Harper; Amy J. Johnson; John C. Byrd; Leslie A. Andritsos

doi:10.1016/j.leukres.2014.05.011

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

Kami Maddocks
, Amy S. Ruppert
, Rebekah Browning
, Jeffrey Jones
, Joseph Flynn
, Cheryl Kefauver
, Yue Gao
, Yao Jiang
, Darlene M. Rozewski
, Ming Poi
, Mitch A. Phelps
, Erica Harper
, Amy J. Johnson
, John C. Byrd
, Leslie A. Andritsos

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear. This study determined maximum tolerated dose (MTD) in relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B). Thirty-seven patients were enrolled. MTD was 2.5. mg followed by 5.0. mg continuous. In Cohort A, tumor flare grade 1-2 occurred in 15 patients (50%) and grade 3 in 1 patient (3%). Cohort A had 19 of 23 evaluable (83%) patients, 4 PR (17%) and 15 (65%) stable disease (SD), Cohort B had 6 of 7 patients (86%) with SD. Despite overall response rate not being high, many patients remained on therapy several months with SD.

Original language	English
Pages (from-to)	1025
Number of pages	1
Journal	Leukemia Research
Volume	38
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2014.05.011
State	Published - Sep 2014

Keywords

Chronic Lymphocytic Leukemia
Lenalidomide
Maintenance
Relapse
Tumor flare

Access to Document

10.1016/j.leukres.2014.05.011

Cite this

Maddocks, K., Ruppert, A. S., Browning, R., Jones, J., Flynn, J., Kefauver, C., Gao, Y., Jiang, Y., Rozewski, D. M., Poi, M., Phelps, M. A., Harper, E., Johnson, A. J., Byrd, J. C., & Andritsos, L. A. (2014). A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leukemia Research, 38(9), 1025. https://doi.org/10.1016/j.leukres.2014.05.011

@article{9e144dccca8544209e7d09f38d16eed1,

title = "A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia",

abstract = "Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear. This study determined maximum tolerated dose (MTD) in relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B). Thirty-seven patients were enrolled. MTD was 2.5. mg followed by 5.0. mg continuous. In Cohort A, tumor flare grade 1-2 occurred in 15 patients (50\%) and grade 3 in 1 patient (3\%). Cohort A had 19 of 23 evaluable (83\%) patients, 4 PR (17\%) and 15 (65\%) stable disease (SD), Cohort B had 6 of 7 patients (86\%) with SD. Despite overall response rate not being high, many patients remained on therapy several months with SD.",

keywords = "Chronic Lymphocytic Leukemia, Lenalidomide, Maintenance, Relapse, Tumor flare",

author = "Kami Maddocks and Ruppert, \{Amy S.\} and Rebekah Browning and Jeffrey Jones and Joseph Flynn and Cheryl Kefauver and Yue Gao and Yao Jiang and Rozewski, \{Darlene M.\} and Ming Poi and Phelps, \{Mitch A.\} and Erica Harper and Johnson, \{Amy J.\} and Byrd, \{John C.\} and Andritsos, \{Leslie A.\}",

year = "2014",

month = sep,

doi = "10.1016/j.leukres.2014.05.011",

language = "English",

volume = "38",

pages = "1025",

journal = "Leukemia Research",

issn = "0145-2126",

number = "9",

}

Maddocks, K, Ruppert, AS, Browning, R, Jones, J, Flynn, J, Kefauver, C, Gao, Y, Jiang, Y, Rozewski, DM, Poi, M, Phelps, MA, Harper, E, Johnson, AJ, Byrd, JC & Andritsos, LA 2014, 'A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia', Leukemia Research, vol. 38, no. 9, pp. 1025. https://doi.org/10.1016/j.leukres.2014.05.011

TY - JOUR

T1 - A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

AU - Maddocks, Kami

AU - Ruppert, Amy S.

AU - Browning, Rebekah

AU - Jones, Jeffrey

AU - Flynn, Joseph

AU - Kefauver, Cheryl

AU - Gao, Yue

AU - Jiang, Yao

AU - Rozewski, Darlene M.

AU - Poi, Ming

AU - Phelps, Mitch A.

AU - Harper, Erica

AU - Johnson, Amy J.

AU - Byrd, John C.

AU - Andritsos, Leslie A.

PY - 2014/9

Y1 - 2014/9

N2 - Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear. This study determined maximum tolerated dose (MTD) in relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B). Thirty-seven patients were enrolled. MTD was 2.5. mg followed by 5.0. mg continuous. In Cohort A, tumor flare grade 1-2 occurred in 15 patients (50%) and grade 3 in 1 patient (3%). Cohort A had 19 of 23 evaluable (83%) patients, 4 PR (17%) and 15 (65%) stable disease (SD), Cohort B had 6 of 7 patients (86%) with SD. Despite overall response rate not being high, many patients remained on therapy several months with SD.

AB - Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear. This study determined maximum tolerated dose (MTD) in relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B). Thirty-seven patients were enrolled. MTD was 2.5. mg followed by 5.0. mg continuous. In Cohort A, tumor flare grade 1-2 occurred in 15 patients (50%) and grade 3 in 1 patient (3%). Cohort A had 19 of 23 evaluable (83%) patients, 4 PR (17%) and 15 (65%) stable disease (SD), Cohort B had 6 of 7 patients (86%) with SD. Despite overall response rate not being high, many patients remained on therapy several months with SD.

KW - Chronic Lymphocytic Leukemia

KW - Lenalidomide

KW - Maintenance

KW - Relapse

KW - Tumor flare

UR - https://www.scopus.com/pages/publications/84906933911

U2 - 10.1016/j.leukres.2014.05.011

DO - 10.1016/j.leukres.2014.05.011

M3 - Article

C2 - 25082342

AN - SCOPUS:84906933911

SN - 0145-2126

VL - 38

SP - 1025

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this